PMID- 36362314
OWN - NLM
STAT- MEDLINE
DCOM- 20221114
LR  - 20221117
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 21
DP  - 2022 Nov 4
TI  - Prolyl Carboxypeptidase Activity Is Present in Human Adipose Tissue and Is 
      Elevated in Serum of Obese Men with Type 2 Diabetes.
LID - 10.3390/ijms232113529 [doi]
LID - 13529
AB  - Prolyl carboxypeptidase (PRCP) is involved in metabolic disorders by hydrolyzing 
      anorexigenic peptides. A link between serum PRCP activity and obesity has been 
      reported, but its origin/source is still unclear. Previously proven correlations 
      between human serum PRCP activity and the amount of adipose tissue may suggest 
      that adipose tissue is an important source of circulating PRCP. We investigated 
      PRCP activity in visceral, subcutaneous adipose tissue (VAT and SCAT), skeletal 
      muscle tissue and serum of lean and obese men with or without type 2 diabetes 
      (T2D). Correlations between PRCP activity, metabolic and biochemical parameters 
      and immune cell populations were assessed. PRCP activity was the highest in VAT, 
      compared to SCAT, and was very low in skeletal muscle tissue in the overall 
      group. Serum PRCP activity was significantly higher in T2-diabetic obese men, 
      compared to lean and obese non-diabetic men, and was positively correlated with 
      glycemic control. A positive correlation was observed between serum PRCP activity 
      and VAT immune cell populations, which might indicate that circulating PRCP 
      activity is deriving rather from the immune fraction than from adipocytes. In 
      conclusion, PRCP activity was observed in human adipose tissue for the first time 
      and serum PRCP activity is correlated with T2D in obese men.
FAU - De Hert, Emilie
AU  - De Hert E
AUID- ORCID: 0000-0002-6094-4455
AD  - Laboratory of Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and 
      Veterinary Sciences, University of Antwerp, 2610 Wilrijk, Belgium.
FAU - Verboven, Kenneth
AU  - Verboven K
AUID- ORCID: 0000-0002-3799-5430
AD  - REVAL-Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt 
      University, 3590 Diepenbeek, Belgium.
AD  - BIOMED-Biomedical Research Center, Faculty of Medicine and Life Sciences, Hasselt 
      University, 3590 Diepenbeek, Belgium.
FAU - Wouters, Kristiaan
AU  - Wouters K
AUID- ORCID: 0000-0001-7127-6950
AD  - Cardiovascular Research Institute Maastricht (CARIM), Department of Internal 
      Medicine, Maastricht University Medical Centre+, 6229 ER Maastricht, The 
      Netherlands.
FAU - Jocken, Johan W E
AU  - Jocken JWE
AD  - Department of Human Biology, NUTRIM School of Nutrition and Translational 
      Research in Metabolism, Maastricht University Medical Centre+, 6229 ER 
      Maastricht, The Netherlands.
FAU - De Meester, Ingrid
AU  - De Meester I
AUID- ORCID: 0000-0002-3421-0124
AD  - Laboratory of Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and 
      Veterinary Sciences, University of Antwerp, 2610 Wilrijk, Belgium.
LA  - eng
GR  - 1S22417N/Research Foundation - Flanders/
GR  - S001017N/Research Foundation - Flanders/
GR  - GOA BOF 2015 No. 30729/University of Antwerp/
GR  - Veni 916.12.056/NWO_/Dutch Research Council/Netherlands
GR  - 2013T143/The Netherlands Heart Foundation/
GR  - CIG 322070/Seventh Framework Program/
PT  - Journal Article
DEP - 20221104
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - EC 3.4.- (Carboxypeptidases)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/metabolism
MH  - Obesity/metabolism
MH  - Adipose Tissue/metabolism
MH  - Subcutaneous Fat/metabolism
MH  - Carboxypeptidases/metabolism
PMC - PMC9655216
OTO - NOTNLM
OT  - diabetes
OT  - human adipose tissue
OT  - metabolic disorders
OT  - obesity
OT  - prolyl carboxypeptidase
COIS- The authors declare no conflict of interest.
EDAT- 2022/11/12 06:00
MHDA- 2022/11/15 06:00
PMCR- 2022/11/04
CRDT- 2022/11/11 01:29
PHST- 2022/10/10 00:00 [received]
PHST- 2022/10/31 00:00 [revised]
PHST- 2022/11/02 00:00 [accepted]
PHST- 2022/11/11 01:29 [entrez]
PHST- 2022/11/12 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/11/04 00:00 [pmc-release]
AID - ijms232113529 [pii]
AID - ijms-23-13529 [pii]
AID - 10.3390/ijms232113529 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Nov 4;23(21):13529. doi: 10.3390/ijms232113529.